Company news
BridgeBio Oncology Therapeutics, Inc. news in 2026
BridgeBio Oncology Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
November 10, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 12, 2026
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
September 8, 2026
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 11, 2026
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 12, 2026
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
April 22, 2026
BBOT Presents Preclinical Data Showing RAS: PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
April 21, 2026
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
April 20, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 12, 2026
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 18, 2026
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
March 6, 2026
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
March 5, 2026
BBOT to Participate in Upcoming Investor Healthcare Conferences
February 12, 2026
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
January 6, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 35 slides · September 2026